Notice of Special Interest: Achieving Tissue Robustness Through Harnessing Immune System Plasticity
https://grants.nih.gov/grants/guide/notice-files/NOT-DE-22-005.html
april 26, 2022pa-20-185 - nih research project grant (parent r01 clinical trial not allowed)pa-20-195 - nih exploratory/developmental research grant program (parent r21 clinical trial not allowed)pa-20-184 - research project grant (parent r01 basic experimental studies with humans required)pa-20-196 - nih exploratory/developmental research grant program (parent r21 basic experimental studies with humans required)national institute of dental and craniofacial research (nidcr)nidcr announces its interest in encouraging state-of-the-art, systematic research approaches to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations, and to examine immune mechanisms of protection against recurrence of chronic inflammation in response to infectious and autoimmune diseases of dental, oral, and craniofacial (doc) tissues. the expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward protection against episodic recurrence and preventative disease management in a patient-specific manner across the lifespan.backgroundthe oral mucosal barrier is constantly exposed to a plethora of triggers, including a diverse microbiome, ongoing damage from mastication, and dietary and airborne antigens, all of which require immune control of its barrier function. recent advances in understanding diseases and conditions involving doc tissues – periodontitis, peri-implantitis, temporomandibular joint disorders (tmd), oral and oropharyngeal cancers, sjögren’s disease, and hiv/aids with its associated oral opportunistic infections, among others demonstrate that the immune system significantly contributes to disease onset, progression, and persistence. for example:while progress to date has been encouraging, critical scientific gaps exist regarding our understanding of the relationship between immune system control during maintenance of oral health and disease pathogenesis. moreover, mechanisms underlying male/female- based, age-related differences in immune reactivity, recurrence-related oral sequelae, oral symptoms presentation and treatment options remain to be understood. inflammation-driven phenotypic plasticity and its effects on the immune landscape of chronic oral inflammation and tumor development, progression and metastasis are yet to be elucidated. specifically, how these tissue-specific cues participate in the training of immune responsiveness at the oral site and the mechanisms mediating homeostatic immunity at this interface remain to be defined. understanding the plasticity of tissue-resident and hematopoietic immune sentinels enriched at the oral mucosal surfaces, and their crosstalk with the microenvironment, will shed light on the mechanisms of persistence and immune memory in the oral cavity. this nosi will address these gaps by capitalizing on recent discoveries of the immunological basis of doc diseases and technological progress in the field. for example:these and other critical developments identified a strong need to: 1) advance knowledge of immune training, immune memory and homeostatic immunity of doc environment, and 2) further develop and adapt novel tools and technologies for precise modulation of immune system plasticity to restore normal homeostasis of doc tissues. the expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based doc therapies that shift a balance between degenerative and regenerative processes toward disease management in a patient-specific manner across lifespan.specific areas of intereststudies that propose the testing of immune modulators that are already in early or late phases of clinical trials are discouraged unless proposed in the context of studying combination therapies with other novel targeted agents; studies that involve the testing of novel immune modulators are strongly encouraged.application and submission informationthis notice applies to due dates on or after june 5, 2022 and subsequent receipt dates through september 8, 2025.submit applications for this initiative using one of the following funding opportunity announcements (foas) or any reissues of these announcement through the expiration date of this notice.foatitlefirst available due datepa-20-185nih research project grant (parent r01 clinical trial not allowed)june 5, 2022pa-20-195nih exploratory/developmental research grant program (parent r21 clinical trial not allowed)june 16, 2022all instructions in the sf424 (r&r) application guide and the funding opportunity announcement used for submission must be followed, with the following additions:applications nonresponsive to terms of this nosi will not be considered for the nosi initiative.scientific/research contact(s)preethi chander, phd national institute of dental and craniofacial research (nidcr) phone: 301-827-4620 email: preethi.chander@nih.govpeer review contact(s)examine your era commons account for review assignment and contact information (information appears two weeks after the submission due date).financial/grants management contact(s)diana rutberg, mba national institute of dental and craniofacial research (nidcr) telephone: 301-564-4798 email: rutbergd@mail.nih.govweekly toc for this announcement nih funding opportunities and noticesnote: for help accessing pdf, rtf, ms word, excel, powerpoint, audio or video files, see help downloading files.